Trial Profile
An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Retigabine (Primary)
- Indications Complex partial epilepsy; Partial epilepsies
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies
- 31 Aug 2012 Planned End Date changed from 1 Jul 2013 to 1 Dec 2012 as reported by ClinicalTrials.gov (Parent trial: NCT01227902).
- 31 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (Parent trial: NCT01227902).